USPTO allows patent application from Provectus for treatment of hematologic diseases
Knoxville-based Provectus Biopharmaceuticals Inc. has announced that the United States Patent and Trademark Office (USPTO) has allowed U.S. patent application 16/688,319 for the treatment of hematologic diseases. Titled “Composition and Method for Treating Hematologic Cancers,” the application covers the use of PV-10, a formulation of Provectus’ immunogenic-small molecule and pharmaceutical-grade rose bengal sodium (RBS) for the treatment. According to the news release, in vivo data of mice with acute lymphoblastic leukemia receiving oral PV-10 showed increased survival compared to controls.
This allowed patent application will be the first Provectus patent award in hematology from the USPTO. Innovate Calgary, the innovation company of the University of Calgary, is a co-assignee and Aru Narendran, MD, PhD of the University of Calgary’s Cumming School of Medicine is a co-inventor on the allowed patent application.
